Understanding the health and housing experiences of refugees and other migrant populations experiencing homelessness or vulnerable housing: a systematic review …

…, Q Alkhateeb, C Mathew, G Khalaf… - … Open Access Journal, 2021 - cmajopen.ca
Background: A growing number of migrants experience precarious housing situations
worldwide, but little is known about their health and housing experiences. The objective of this …

Phylogeny of Salmonidae family inffered from D-loop mitochondrial marker

M Khalaf, GO Popa, SE Georgescu, A Dudu… - Scientific Papers Animal …, 2014 - spasb.ro
Salmonids are a heterogeneous group of fish classified in one family–Salmonidae. These
species are natives of the northern hemisphere, but currently have been introduced in many …

[HTML][HTML] Prospective assessment of the decision-making impact of the Breast Cancer Index in recommending extended adjuvant endocrine therapy for patients with …

…, V Bossuyt, M DiGiovanna, M Abu-Khalaf… - Breast Cancer Research …, 2015 - Springer
Extended adjuvant endocrine therapy (10 vs. 5 years) trials have demonstrated improved
outcomes in early-stage estrogen receptor (ER)-positive breast cancer; however, the absolute …

Impacts of early guideline-directed 21-gene recurrence score testing on adjuvant therapy decision making

…, KB Adelson, A Silber, M Abu-Khalaf… - Journal of oncology …, 2017 - ascopubs.org
Purpose: The 21-gene recurrence score (RS) assay is used to help formulate adjuvant
chemotherapy recommendations for patients with estrogen receptor–positive, early-stage breast …

Prospective study of the decision-making impact of the Breast Cancer Index in the selection of patients with ER+ breast cancer for extended endocrine therapy.

…, V Bossuyt, M DiGiovanna, MM Abu-Khalaf… - 2015 - ascopubs.org
538 Background: The Breast Cancer Index (BCI) has been validated to quantify an
individualized risk of late recurrence and to predict likelihood of benefit from extended endocrine …

Long-term assessment of cardiac function after dose-dense and-intense sequential doxorubicin (A), paclitaxel (T), and cyclophosphamide (C) as adjuvant therapy for …

MM Abu-Khalaf, V Juneja, GG Chung… - Breast cancer research …, 2007 - Springer
Objectives This study evaluated the incidence of late cardiotoxicity after dose-dense and -intense
adjuvant sequential doxorubicin (A), paclitaxel (T), and cyclophosphamide (C) for …

[PDF][PDF] Characterization of the relationship between complete pathologic response from neoadjuvant treatment and survival measures in breast cancer subtypes …

C Hatzis, WF Symmans, M Abu-Khalaf, G Chung… - researchgate.net
Background The FDA has recently approved the use of complete pathologic response (pCR)
as an endpoint in the neoadjuvant treatment of highrisk early stage breast cancer to …

[HTML][HTML] Prevalence of asthma control in adult patients in Kirkuk City

BJ Kamal, MA Khalaf - Medical Journal of Babylon, 2023 - journals.lww.com
… on the GINA guidelines. The results showed that in the 5 years between the GINA guidelines
… in the management of asthma made by the GINA guidelines within the last 10 years. [ 5 ] …

Abstract P5-13-02: neoadjuvant aromatase inhibitor therapy plus the mTOR inhibitor everolimus in postmenopausal women with hormone receptor positive/HER2 …

MM Abu-Khalaf, K Aderhold, M Marczyk, G Chung… - Cancer Research, 2020 - AACR
Background: Breast cancer (BC) patients (pts) with Oncotype Dx recurrence scores (RS) ≤
25 represent a large fraction of BC cases. The TAILORx study demonstrated that these pts …

Sirolimus and trastuzumab combination therapy for HER2-positive metastatic breast cancer after progression on prior trastuzumab therapy

…, MP DiGiovanna, L Harris, MM Abu-Khalaf - Breast cancer research …, 2015 - Springer
Constitutive activation of the PI3K/Akt/mTOR pathway has been suggested as a mechanism
of resistance to trastuzumab therapy. This phase II trial was designed to evaluate the safety …